Ten things you should know about protein kinases: IUPHAR Review 14

被引:260
作者
Fabbro, Doriano [1 ]
Cowan-Jacob, Sandra W. [2 ]
Moebitz, Henrik [2 ]
机构
[1] PIQUR Therapeut, CH-4057 Basel, Switzerland
[2] Novartis Inst Biomed Res, Basel, Switzerland
基金
英国惠康基金;
关键词
CHRONIC MYELOID-LEUKEMIA; CELL LUNG-CANCER; TYROSINE KINASE; SMALL-MOLECULE; BCR-ABL; ACQUIRED-RESISTANCE; SELECTIVE INHIBITOR; IRREVERSIBLE INHIBITORS; TARGETING KINASES; MAP KINASE;
D O I
10.1111/bph.13096
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Many human malignancies are associated with aberrant regulation of protein or lipid kinases due to mutations, chromosomal rearrangements and/or gene amplification. Protein and lipid kinases represent an important target class for treating human disorders. This review focus on the 10 things you should know about protein kinases and their inhibitors', including a short introduction on the history of protein kinases and their inhibitors and ending with a perspective on kinase drug discovery. Although the 10 things' have been, to a certain extent, chosen arbitrarily, they cover in a comprehensive way the past and present efforts in kinase drug discovery and summarize the status quo of the current kinase inhibitors as well as knowledge about kinase structure and binding modes. Besides describing the potentials of protein kinase inhibitors as drugs, this review also focus on their limitations, particularly on how to circumvent emerging resistance against kinase inhibitors in oncological indications.
引用
收藏
页码:2675 / 2700
页数:26
相关论文
共 296 条
[51]   The role of protein phosphorylation in human health and disease - Delivered on June 30th 2001 at the FEBS Meeting in Lisbon [J].
Cohen, P .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2001, 268 (19) :5001-5010
[52]   Protein kinases - the major drug targets of the twenty-first century? [J].
Cohen, P .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :309-315
[53]   The origins of protein phosphorylation [J].
Cohen, P .
NATURE CELL BIOLOGY, 2002, 4 (05) :E127-E130
[54]   Discovery and Characterization of Non-ATP Site Inhibitors of the Mitogen Activated Protein (MAP) Kinases [J].
Comess, Kenneth M. ;
Sun, Chaohong ;
Abad-Zapatero, Cele ;
Goedken, Eric R. ;
Gum, Rebecca J. ;
Borhani, David W. ;
Argiriadi, Maria ;
Groebe, Duncan R. ;
Jia, Yong ;
Clampit, Jill E. ;
Haasch, Deanna L. ;
Smith, Harriet T. ;
Wang, Sanyi ;
Song, Danying ;
Coen, Michael L. ;
Cloutier, Timothy E. ;
Tang, Hua ;
Cheng, Xueheng ;
Quinn, Christopher ;
Liu, Bo ;
Xin, Zhili ;
Liu, Gang ;
Fry, Elizabeth H. ;
Stoll, Vincent ;
Ng, Teresa I. ;
Banach, David ;
Marcotte, Doug ;
Burns, David J. ;
Calderwood, David J. ;
Hajduk, Philip J. .
ACS CHEMICAL BIOLOGY, 2011, 6 (03) :234-244
[55]   Development of thioquinazolinones, allosteric Chk1 kinase inhibitors [J].
Converso, Antonella ;
Hartingh, Timothy ;
Garbaccio, Robert M. ;
Tasber, Edward ;
Rickert, Keith ;
Fraley, Mark E. ;
Yan, Youwei ;
Kreatsoulas, Constantine ;
Stirdivant, Steve ;
Drakas, Bob ;
Walsh, Eileen S. ;
Hamilton, Kelly ;
Buser, Carolyn A. ;
Mao, Xianzhi ;
Abrams, Marc T. ;
Beck, Stephen C. ;
Tao, Weikang ;
Lobell, Rob ;
Sepp-Lorenzino, Laura ;
Zugay-Murphy, Joan ;
Sardana, Vinod ;
Munshi, Sanjeev K. ;
Jezequel-Sur, Sylvie Marie ;
Zuck, Paul D. ;
Hartman, George D. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (04) :1240-1244
[56]   PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease [J].
Cools, J ;
Stover, EH ;
Boulton, CL ;
Gotlib, J ;
Legare, RD ;
Amaral, SM ;
Curley, DP ;
Duclos, N ;
Rowan, R ;
Kutok, JL ;
Lee, BH ;
Williams, IR ;
Coutre, SE ;
Stone, RM ;
DeAngelo, DJ ;
Marynen, P ;
Manley, PW ;
Meyer, T ;
Fabbro, D ;
Neuberg, D ;
Weisberg, E ;
Griffin, JD ;
Gilliland, DG .
CANCER CELL, 2003, 3 (05) :459-469
[57]   Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemia [J].
Cools, J ;
Mentens, N ;
Furet, P ;
Fabbro, D ;
Clark, JJ ;
Griffin, JD ;
Marynen, P ;
Gilliland, DG .
CANCER RESEARCH, 2004, 64 (18) :6385-6389
[58]  
Corcoran RB, 2011, ONCOTARGET, V2, P336
[59]   The PI3K Pathway As Drug Target in Human Cancer [J].
Courtney, Kevin D. ;
Corcoran, Ryan B. ;
Engelman, Jeffrey A. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) :1075-1083
[60]   Structural biology of protein tyrosine kinases [J].
Cowan-Jacob, S. W. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2006, 63 (22) :2608-2625